CLDN10 promotes a malignant phenotype of osteosarcoma cells via JAK1/Stat1 signaling
- 122 Downloads
In our previous study, the expression profile of tight junction (TJ) protein claudins (CLDNs) in human osteosarcoma (OS) cells was examined, and the data found the CLDN10 was high expressed in OS cells versus fetal osteoblast cells. Hence, we aim to determine the impacts and the molecular mechanisms of CLDN10 in the metastatic phenotype of OS. The exact expression profiles of CLDN10 and phosphorylated Janus kinase 1 (JAK1) in noncancerous bone tissues and OS tissues were detected via a western blotting and immunohistochemistry method. The OS cells with CLDN10 or JAK1 silencing was established via an RNA interference (RNAi) method, and an osteoblast cell line stably expressing CLDN10 was established via cell transfection. Then, the transfection effects and activation states of JAK1/ signal transducer and activator of transcription1 (Stat1) pathway in OS and osteoblast cells were detected via a western blotting assay. Moreover, the metastatic ability of osteoblast cells and OS cells in vitro were evaluated by means of a cell counting kit-8 (CCK8) assay, colony formation assay in soft agar, transwell assay and wound-healing experiment. The present data revealed that CLDN10 and phospho-JAK1 were up-regulated in OS tissues compared with noncancerous bone tissues. Genetic loss of CLDN10 or JAK1 inhibited the activation of the Stat1 and the malignant phenotype in OS cells. To sum up, our study suggested the CLDN10 enhanced the metastatic phenotype of OS cells via the activation of the JAK1/Stat1 signaling pathway.
KeywordsClaudin-10 Osteosarcoma Janus kinase 1 Signal transducer and activator of transcription1 Metastasis
Cell counting kit-8
Janus kinase 1
Signal transducer and activator of transcription1
We would like to thank American Journal Experts (AJE) for English language editing. This manuscript was edited for English language by American Journal Experts (AJE).
XZ, XW and AW performed the experiments and analyzed the data. MZ and QL contributed to the conception and design of the study. TL revised the manuscript critically for important intellectual content. All authors read and approved the final manuscript.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Ethics approval (approval no. SDU06384) was approved by the Ethics Committee of Central Hospital of Zibo, Affiliated with Shandong University. This article does not contain any studies with animals performed by any of the authors. The informed consent for participation was obtained from all patients and their parents who participated in this study in an appropriate method.
Consent for publication
Written informed consent was obtained from all patients and their parents who participated in this study.
- de Souza WF, Fortunato-Miranda N, Robbs BK, de Araujo WM, de-Freitas-Junior JC, Bastos LG, Viola JP, Morgado-Diaz JA (2013) Claudin-3 overexpression increases the malignant potential of colorectal cancer cells: roles of ERK1/2 and PI3K-Akt as modulators of EGFR signaling. PLoS One 8(9):e74994. https://doi.org/10.1371/journal.pone.0074994 CrossRefGoogle Scholar
- Jeansonne B, Lu Q, Goodenough DA, Chen YH (2003) Claudin-8 interacts with multi-PDZ domain protein 1 (MUPP1) and reduces paracellular conductance in epithelial cells. Cell Mol Biol 49(1):13–21Google Scholar
- Koval M (2013) Claudin heterogeneity and control of lung tight junctions. Annu Rev Physiol 75:551–567. https://doi.org/10.1146/annurev-physiol-030212-183809 CrossRefGoogle Scholar
- Merino-Gracia J, Costas-Insua C, Canales MA, Rodriguez-Crespo I (2016) Insights into the C-terminal peptide binding specificity of the PDZ domain of neuronal nitric-oxide synthase: CHARACTERIZATION OF THE INTERACTION WITH THE TIGHT JUNCTION PROTEIN CLAUDIN-3. J Biol Chem 291(22):11581–11595. https://doi.org/10.1074/jbc.M116.724427 CrossRefGoogle Scholar
- Micke P, Mattsson JS, Edlund K, Lohr M, Jirstrom K, Berglund A, Botling J, Rahnenfuehrer J, Marincevic M, Ponten F, Ekman S, Hengstler J, Woll S, Sahin U, Tureci O (2014) Aberrantly activated claudin 6 and 18.2 as potential therapy targets in non-small-cell lung cancer. Int J Cancer 135(9):2206–2214. https://doi.org/10.1002/ijc.28857 CrossRefGoogle Scholar
- Ouban A, Ahmed AA (2010) Claudins in human cancer: a review Histology and histopathology 25:83–90. https://doi.org/10.14670/HH-25.83
- Suh Y, Yoon CH, Kim RK, Lim EJ, Oh YS, Hwang SG, An S, Yoon G, Gye MC, Yi JM, Kim MJ, Lee SJ (2017) Claudin-1 induces epithelial-mesenchymal transition through activation of the c-Abl-ERK signaling pathway in human liver cells. Oncogene 36(8):1167–1168. https://doi.org/10.1038/onc.2016.294 CrossRefGoogle Scholar
- Yang Y, Yang H, McNutt MA, Xiong F, Nie X, Li L, Zhou R (2008) LAPTM4B overexpression is an independent prognostic marker in ovarian carcinoma. Oncol Rep 20(5):1077–1083Google Scholar
- Zavala-Zendejas VE, Torres-Martinez AC, Salas-Morales B, Fortoul TI, Montano LF, Rendon-Huerta EP (2011) Claudin-6, 7, or 9 overexpression in the human gastric adenocarcinoma cell line AGS increases its invasiveness, migration, and proliferation rate. Cancer Investig 29(1):1–11. https://doi.org/10.3109/07357907.2010.512594 CrossRefGoogle Scholar